Company Directory - Biogen
Company Details - Biogen
Biogen
WebsiteA biotechnology company specializing in discovering, developing, and delivering innovative therapies for neurological diseases.
CCI Score
CCI Score: Biogen
-26.78
0.02%
Latest Event
Biogen PAC Contributions to Federal Candidates
Biogen, through its PAC, contributed $23,000 to federal candidates during the 2023-2024 election cycle, as reported by OpenSecrets based on FEC data released on February 06, 2025.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
Biogen is currently rated as an Accomplice.
Latest Events
- FEB062025
Biogen, through its PAC, contributed $23,000 to federal candidates during the 2023-2024 election cycle, as reported by OpenSecrets based on FEC data released on February 06, 2025.
-20
Political Contributions and Lobbying Efforts
April 2
The political contribution of $23,000, while relatively modest, exemplifies corporate influence in politics. From an anti-fascist perspective, such donations, even when not explicitly tied to far-right candidates, contribute to the broader system of corporate political influence, which can undermine democratic processes and potentially support authoritarian trends.
Biogen PAC Contributions to Federal Candidates • OpenSecrets
- JAN012024
An OpenSecrets profile on Biogen detailed that in the 2024 cycle, the company contributed $309,824 and spent $4,140,000 on lobbying. It additionally reported significant revolving door activity, with many Biogen lobbyists having previously held government positions, raising concerns about corporate influence and potential regulatory capture.
-60
Political Contributions and Lobbying Efforts
April 2
Biogen's reported political contributions and substantial lobbying expenditures in 2024 signal a significant investment in influencing political processes. This level of spending can enable undue corporate influence and regulatory capture, which are contrary to democratic accountability and ideal anti-fascist practices.
-40
Executive Political Engagement
April 2
The data indicating that a significant portion of Biogen lobbyists have previously held government positions suggests a revolving door that can compromise regulatory integrity and amplify corporate interests, undermining democratic accountability.
- SEP012023
Biogen finalized a $900 million settlement over allegations of paying illegal kickbacks to doctors to promote its drugs, resulting in a settlement for False Claims Act violations.
-50
Business Practices and Ethical Responsibility
April 2
The settlement stems from allegations that Biogen engaged in unethical business practices by paying illegal kickbacks to doctors, undermining fair competition and ethical standards. Such actions erode public trust in corporate governance and signal deeper issues of accountability in corporate practice.
Pharma, whistleblower lessons learned from $900M Biogen settlement
- JUL012023
Biogen has made public its political contributions disclosures for multiple periods (January 2022 - December 2022 and January 2023 - December 2023), enhancing corporate transparency regarding its political funding and activities.
+50
Political Contributions and Lobbying Efforts
April 2
The publication of detailed political contributions disclosures demonstrates a commitment to transparency and accountability. By making this information readily available, Biogen enables public scrutiny of its political funding practices, which is a positive step against opaque corporate political behavior. This transparency aligns with anti-authoritarian principles by allowing stakeholders to assess and challenge any potential support for harmful political agendas.
- JAN012023
Biogen disclosed a $900M agreement as part of a whistleblower kickback lawsuit, raising serious ethical concerns over its business practices in pharmaceutical marketing.
-70
Business Practices and Ethical Responsibility
April 2
The disclosure of a $900M kickback agreement as part of a whistleblower suit indicates deeply unethical business practices. This arrangement suggests potential systemic issues with corporate transparency and accountability in Biogen's operations, which could undermine public trust and ethical standards in the pharmaceutical sector.
Biogen discloses $900M agreement in whistleblower kickback suit
- JAN012023
Biogen published its 2023 Corporate Responsibility Report, highlighting efforts in environmental, social, and governance (ESG) practices, including sustainable initiatives, community engagement, and a focus on health equity. The report underscores Biogen's commitment to responsible business practices and long-term positive impact.
+15
Business Practices and Ethical Responsibility
April 2
The report details Biogen's focus on responsible corporate practices including ESG, sustainable operations, and community engagement. These actions support a progressive framework that prioritizes public welfare and ethical governance, aligning with anti-authoritarian values.
- SEP012022
Biogen reached a $900 million settlement following allegations that it paid illegal kickbacks to physicians to promote its multiple sclerosis treatments, undermining public trust in federal healthcare programs.
-50
Public and Political Behavior
April 2
The bribery allegations indicate an attempt to manipulate prescription practices and indirectly influence federal healthcare policies, thereby undermining public political trust. Such actions contribute to a climate where ethical standards in public behavior are compromised.
US Pharma Firm Biogen Settles for $900 Million with Whistleblower in Bribe Case
-70
Business Practices and Ethical Responsibility
April 2
The settlement underscores severe breaches in ethical business practices, revealing that Biogen engaged in large-scale illegal kickback schemes. The significant financial penalty reflects the gravity of undermining corporate ethical responsibilities and eroding trust in the industry.
US Pharma Firm Biogen Settles for $900 Million with Whistleblower in Bribe Case
- JUL282022
Biogen agreed to pay $900 million to settle allegations that it provided lavish kickbacks to doctors to promote its MS drugs, following claims made by a whistleblower amid an impending trial.
-80
Business Practices and Ethical Responsibility
April 2
Biogen's alleged practice of overpaying doctors through extravagant speaking and consulting programs to boost its MS drug sales represents a clear breach of ethical business practices. This behavior not only violates anti-kickback statutes but also undermines trust in the healthcare system, thereby contributing to broader systemic issues that can indirectly support authoritarian misuse of power through corporate malfeasance.
Biotech Company Agrees To $900 Million Settlement in FCA Case
Alternatives
Belgium (Ghent), Belgium
79.03
Raleigh, USA
56.52
Cranbury, United States
-15.14
Basel, Switzerland
-19.75
Seattle, United States
-38.14
Menlo Park, United States
-49.80
Corporation
10.44
Corporation
0.00
Corporation
0.00
Corporation
-52.53
Corporate Financials
- Revenue
- 2022
- $3.54B
- Total Assets
- 2022
- $11.40B
- Operating Income
- 2022
- $1.34B
- Total Equity
- 2022
- $10.62B
Employees: 7,800
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 621511
- Medical Laboratories
- 541711
- Research and Development in Biotechnology